Category Stock Exchange

Viking Therapeutics: VK2735 Promise Meets Execution Risk

[ad_1] Executive Summary Viking Therapeutics remains entirely devoid of commercialized products and generates zero revenue, making its valuation highly dependent on the future clinical and regulatory success of its lead asset, VK2735, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic…